Proteomic Validation of Protease Drug Targets: Pharmacoproteomics of Matrix Metalloproteinase Inhibitor Drugs Using Isotope-Coded Affinity Tag Labelling and Tandem Mass Spectrometry

Author(s): G. S. Butler, C. M. Overall

Journal Name: Current Pharmaceutical Design

Volume 13 , Issue 3 , 2007

Become EABM
Become Reviewer
Call for Editor


We illustrate the use of quantitative proteomics, namely isotope-coded affinity tag labelling and tandem mass spectrometry, to assess the targets and effects of the blockade of matrix metalloproteinases by an inhibitor drug in a breast cancer cell culture system. Treatment of MT1-MMP-transfected MDA-MB-231 cells with AG3340 (Prinomastat) directly affected the processing a multitude of matrix metalloproteinase substrates, and indirectly altered the expression of an array of other proteins with diverse functions. Therefore, broad spectrum blockade of MMPs has wide-ranging biological consequences. In this human breast cancer cell line, secreted substrates accumulated uncleaved in the conditioned medium and plasma membrane protein substrates were retained on the cell surface, due to reduced processing and shedding of these proteins (cell surface receptors, growth factors and bioactive molecules) to the medium in the presence of the matrix metalloproteinase inhibitor. Hence, proteomic investigation of drug-perturbed cellular proteomes can identify new protease substrates and at the same time provides valuable information for target validation, drug efficacy and potential side effects prior to commitment to clinical trials.

Keywords: Protease, anti-proteolytic drugs, MMP, proteomics, degradomics, pharmacoproteomics, ICAT, side effects

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2007
Page: [263 - 270]
Pages: 8
DOI: 10.2174/138161207779313524
Price: $65

Article Metrics

PDF: 3